Summary of Fosun Pharma Conference Call Company Overview - Fosun Pharma's total revenue for 2024 is approximately 40.3 billion RMB, with innovative drug revenue nearing 8 billion RMB, showing a continuous increase in proportion [2][3] Core Business Segments - The company operates three main business segments: - Pharmaceutical segment: Revenue exceeds 28.9 billion RMB, accounting for over 70% of total revenue [3] - Medical device diagnostics segment: Revenue is 4.3 billion RMB, representing about 10% of total revenue [3] - Medical services segment: Revenue is approximately 7.6 billion RMB, making up nearly 19% of total revenue [3] Innovative Drug Highlights - Innovative drug revenue reached nearly 8 billion RMB in 2024, with core products Hanshuozhuang and Hanquyou generating over 1.3 billion RMB and 2.8 billion RMB, respectively [2][4] - Future growth in innovative drug revenue is expected to maintain a 20% growth rate [2][4] - New products in the pipeline include FCN159 for rare tumors and FCN437 for breast cancer [5][14] Medical Device Diagnostics Segment - The medical device diagnostics segment generated 4.3 billion RMB in 2024, with key products including Assystem's long-acting botulinum toxin and the Da Vinci surgical robot [7] - The segment is currently operating at a loss but is expected to improve with the establishment of a major R&D and training base in Shanghai [7] Medical Services Segment - The medical services segment reported approximately 7.6 billion RMB in revenue for 2024, still operating at a loss but showing significant reduction in losses from 800 million RMB in 2022 to 300 million RMB in 2024 [8] Strategic Initiatives - The company is focusing on innovative drugs and high-value medical devices, having exited non-core assets to recover approximately 3 billion RMB for reinvestment in innovation [2][9] - The leadership team has been restructured, emphasizing innovation and internationalization [10][11] R&D Pipeline and New Products - Notable products in the R&D pipeline include ALK inhibitor Furretinib and PD-1 plus VEGFR combination therapy, with some products entering Phase III clinical trials [6] - The company is actively pursuing best-in-class potential products, with several receiving orphan drug designation [6] Financial Management and Shareholder Value - The company has implemented measures to optimize its debt structure and has conducted stock buybacks to protect investor interests, with 300 million RMB repurchased in A-shares and approximately 45 million HKD in Hong Kong shares [4][12] Conclusion - Fosun Pharma is strategically positioning itself for growth in innovative pharmaceuticals and medical devices while managing its financial health and operational efficiency through asset optimization and leadership restructuring [9][10]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： 新提交 | | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | 呈交日期： | 2025年6月26日 | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： 新提交 | | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | 呈交日期： | 2025年6月26日 | | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | ...

Market Performance - A-shares saw a morning surge with the Shanghai Composite Index rising by 1.15% to 3420.57 points, Shenzhen Component Index up 1.68%, and ChiNext Index increasing by 2.3%[1] - The Hong Kong Hang Seng Index closed up 2.06% at 24177.07 points, with the Hang Seng Tech Index rising by 2.14% and the Hang Seng China Enterprises Index increasing by 1.9%[1] - The total trading volume in the Hong Kong market reached 2404.815 billion HKD[1] U.S. Market Trends - All three major U.S. stock indices rose over 1%, with the Dow Jones up 1.19%, S&P 500 increasing by 1.11% to 6092.18 points, and Nasdaq rising by 1.43%[1] - Federal Reserve Chairman Jerome Powell indicated a balanced stance on interest rate cuts, suggesting a wait-and-see approach regarding tariff impacts on the economy[8] Geopolitical Developments - A fragile ceasefire agreement between Israel and Iran remains in place, but the fate of highly enriched uranium is still uncertain, with the International Atomic Energy Agency seeking to return to Iran for verification[8][11] Economic Policies - The People's Bank of China and six other departments issued guidelines to enhance financial support for boosting and expanding consumption, emphasizing structural monetary policy tools and credit support for key service sectors[11]

Core Viewpoint - The document outlines the information disclosure system of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., emphasizing the importance of timely, accurate, and complete disclosure of information that may significantly impact the trading prices of the company's securities and derivatives. Group 1: General Principles - The information disclosure system is established to regulate the disclosure behavior of the company and related parties, ensuring the protection of the company's and investors' legal rights [1][2] - Information disclosure obligations apply to various parties, including the company's board of directors, senior management, shareholders, and other relevant individuals [2][3] - The board of directors is responsible for implementing the information disclosure system, with the chairman as the primary responsible person [3][4] Group 2: Basic Principles of Information Disclosure - Information must be disclosed in a timely and fair manner, ensuring that all investors receive the same information simultaneously [3][4] - Disclosure must be truthful, accurate, complete, and clear, without any misleading statements or significant omissions [3][4] - The company must adhere to legal and regulatory requirements for information disclosure, including those set by the Shanghai Stock Exchange and the Hong Kong Stock Exchange [4][5] Group 3: Content of Information Disclosure - The company is required to prepare and disclose periodic reports, including annual and interim reports, in accordance with relevant regulations [6][7] - Annual reports must include key information such as the company's basic situation, major accounting data, stock and bond issuance, and significant events during the reporting period [7][8] - The company must disclose any risks that may significantly impact its core competitiveness and future development [7][8] Group 4: Temporary Reports - Temporary reports must be disclosed for significant events that may impact the trading prices of the company's securities, including shareholder and board resolutions [9][10] - The company must immediately disclose any major events that investors are not yet aware of, detailing the cause, current status, and potential impact [9][10] Group 5: Internal Management of Information Disclosure - The board secretary's office is responsible for managing information disclosure, coordinating the collection and reporting of information to the board [13][14] - All departments and subsidiaries must report significant events to the board secretary promptly [18][19] - The company must establish internal procedures for the preparation, review, and disclosure of periodic reports [19][20] Group 6: Confidentiality and Accountability - Information disclosure obligations include maintaining confidentiality of undisclosed information and ensuring that insiders do not leak such information [21][22] - Individuals who fail to comply with disclosure requirements or cause significant omissions may face internal penalties and legal liabilities [22][23]

（2025 年修订） 第一条 为了进一步完善公司治理，保证所有股东充分行使权利，根据中国 证券监督管理委员会《上市公司治理准则》 上海复星医药（集团）股份有限公司 累积投票制实施细则 《上市公司独立董事管理办法》 《上海 复星医药（集团）股份有限公司章程》（以下简称"《公司章程》"）及其他有关 规定，特制定本实施细则。 第二条 实施细则所称"董事"包括独立非执行董事和独立非执行董事以外 的董事。 公司在股东会选举两名或两名以上的董事时，应采用累积投票制并适用本实 施细则。公司股东会仅选举或更换一名董事时，以及同时选举或更换一名独立非 执行董事以外的董事（即包括：执行董事、非执行董事）和一名独立非执行董事 时，不适用累积投票制。 在股东会上选举董事时，董事会应当在召开股东会的会议通知中，表明该次 董事选举是否采用累积投票制。 第三条 股东会选举产生的董事人数及结构应符合《公司章程》的规定。 第四条 本实施细则所指的累积投票制，是指股东会在选举两名以上的董事 时采用的一种投票方式。即公司选举董事时，每位股东拥有的投票权数等于其所 持有的股份数乘以应选董事人数的乘积数，每位股东可以将其拥有的全部投票权 数集中投向某 ...

Core Points - The article outlines the independent non-executive director system of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to enhance corporate governance and ensure compliance with relevant laws and regulations [1][2][3] Group 1: General Provisions - The independent non-executive director is defined as a director who does not hold any other position in the company and has no direct or indirect interests that could affect their independent judgment [1] - The independent non-executive directors are required to fulfill their duties diligently and loyally to the company and all shareholders [2] Group 2: Qualifications and Conditions - Candidates for independent non-executive directors must meet specific qualifications, including having at least five years of relevant work experience and a good personal character [6] - Individuals who have significant relationships with the company or its major shareholders are prohibited from serving as independent non-executive directors [3][4] Group 3: Nomination and Election Procedures - The nomination of independent non-executive directors can be proposed by the board or shareholders holding more than 1% of the company's issued shares [8][9] - The election of independent non-executive directors must follow a cumulative voting system if two or more are elected [6] Group 4: Responsibilities and Duties - Independent non-executive directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice to enhance decision-making [15][16] - They have the authority to independently hire external consultants for audits or inquiries [16] Group 5: Performance and Reporting - Independent non-executive directors must submit an annual report detailing their attendance at meetings and their engagement with shareholders [27][28] - The company is required to provide necessary support and resources for independent non-executive directors to perform their duties effectively [32][33] Group 6: Compensation and Insurance - The company is responsible for covering the costs incurred by independent non-executive directors when hiring professional services [36] - A compensation system for independent non-executive directors should be established and disclosed in the annual report [37]

Core Points - The document outlines the rules for the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, aiming to standardize meeting procedures and decision-making processes to enhance governance and decision-making quality [1][3][26] Group 1: Board Structure and Responsibilities - The board of directors is responsible for significant corporate actions, including capital changes, major acquisitions, and internal management structure [3][4] - The board must convene at least four regular meetings annually, with the chairman responsible for calling these meetings [7][10] - The board has the authority to decide on the appointment and remuneration of senior management, including the CEO and other executives [3][5] Group 2: Meeting Procedures - Regular meetings require a minimum of fourteen days' notice, while temporary meetings require three days' notice [11][12] - Proposals for meetings must be clear and submitted with supporting materials [9][10] - Decisions require a majority vote from the attending directors, with specific rules for handling conflicts of interest and ensuring independent director participation [20][22] Group 3: Documentation and Record-Keeping - Meeting records must include details such as date, attendees, agenda, and voting results, and should be signed by participants [23][24] - The board secretary is responsible for maintaining meeting records for ten years and ensuring they are accessible to directors upon request [26][33] - Any resolutions made must be announced according to regulatory requirements, and confidentiality must be maintained until official disclosure [29][30]

第一条 为规范上海复星医药（集团）股份有限公司（以下简称"本公司"、 "复星医药"或"上市公司"）及附属公司（以下合称"本集团"）关联交易行 为，保护本公司和全体股东的合法权益，根据《中华人民共和国公司法》、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会 （以下简称"中国证监会"）《上市公司信息披露管理办法》、《上海证券交易 所股票上市规则》（以下简称"上证所《上市规则》"）、《香港联合交易所有 限公司证券上市规则》（以下简称"联交所《上市规则》"）等法律、法规、规 章、规范性文件以及《上海复星医药（集团）股份有限公司章程》 （以下简称"《公 司章程》"）的有关规定，特制定本制度。 第二条 关联交易应当保证合法性、必要性、合理性和公允性，并保持上市 公司的独立性，不得利用关联交易调节财务指标，损害上市公司利益。 交易各方不得隐瞒关联/连关系或者采取其他手段，规避本公司的关联交易 审议程序和信息披露义务。 上海复星医药（集团）股份有限公司 关联交易管理制度 （2025年修订） 第一章 总 则 第三条 股东会、董事会应当根据本公司证券上市地监管机构以及《公司章 程》的规定对关联交易实 ...

上海复星医药（集团）股份有限公司 信息披露暂缓与豁免业务管理制度 （2025年修订） 第一条 为规范上海复星医药（集团）股份有限公司（以下简称"本公司"或 "上市公司"）信息披露暂缓与豁免行为，依法合规履行信息披露义务，保护投 资者的合法权益，根据《中华人民共和国证券法》、中国证券监督管理委员会《上 市公司信息披露暂缓与豁免管理规定》 《上海证券交易所股票上市规则》 第三条 本公司和其他信息披露义务人应当审慎确定信息披露暂缓、豁免事 项，并履行内部审核程序后方可实施。 第四条 本公司和其他信息披露义务人有确实充分的证据证明拟披露的信息 涉及国家秘密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以 下统称"国家秘密"），依法豁免披露。 （以下简 称"《股票上市规则》"）、《香港联合交易所有限公司证券上市规则》（以下简称 "《香港上市规则》"）、香港《证券及期货条例》、香港证券及期货事务监察委员 会《内幕消息披露指引》 《上海复星医药（集团）股份有限公司章程》 （以下简称 "《公司章程》"）、 《上海复星医药（集团）股份有限公司信息披露制度》 （以下简 称"《信息披露制度》"）等规定，特制定本制度。 第 ...